HomeCompareOCX vs VIG

OCX vs VIG: Dividend Comparison 2026

OCX yields 62.50% · VIG yields 1.64%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OCX wins by $703.6K in total portfolio value
10 years
OCX
OCX
● Live price
62.50%
Share price
$3.20
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$735.9K
Annual income
$177,443.13
Full OCX calculator →
VIG
Vanguard Dividend Appreciation ETF
● Live price
1.64%
Share price
$210.70
Annual div
$3.45
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.4K
Annual income
$179.15
Full VIG calculator →

Portfolio growth — OCX vs VIG

📍 OCX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOCXVIG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OCX + VIG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OCX pays
VIG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OCX
Annual income on $10K today (after 15% tax)
$5,312.50/yr
After 10yr DRIP, annual income (after tax)
$150,826.66/yr
VIG
Annual income on $10K today (after 15% tax)
$139.33/yr
After 10yr DRIP, annual income (after tax)
$152.28/yr
At 15% tax rate, OCX beats the other by $150,674.38/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OCX + VIG for your $10,000?

OCX: 50%VIG: 50%
100% VIG50/50100% OCX
Portfolio after 10yr
$384.1K
Annual income
$88,811.14/yr
Blended yield
23.12%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on OCX right now

OCX
Analyst Ratings
3
Buy
2
Hold
Consensus: Buy
Price Target
$8.06
+151.9% upside vs current
Range: $4.25 — $10.00
Altman Z
-27.0
Piotroski
2/9
VIG
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OCX buys
0
VIG buys
0
No recent congressional trades found for OCX or VIG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOCXVIG
Forward yield62.50%1.64%
Annual dividend / share$2.00$3.45
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$735.9K$32.4K
Annual income after 10y$177,443.13$179.15
Total dividends collected$614.9K$1.7K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: OCX vs VIG ($10,000, DRIP)

YearOCX PortfolioOCX Income/yrVIG PortfolioVIG Income/yrGap
1← crossover$16,950$6,250.00$11,304$163.92+$5.6KOCX
2$28,037$9,900.70$12,759$166.33+$15.3KOCX
3$45,305$15,305.49$14,382$168.52+$30.9KOCX
4$71,591$23,114.13$16,192$170.52+$55.4KOCX
5$110,737$34,135.17$18,210$172.34+$92.5KOCX
6$167,835$49,346.36$20,460$173.98+$147.4KOCX
7$249,481$69,897.34$22,968$175.48+$226.5KOCX
8$364,047$97,102.68$25,763$176.83+$338.3KOCX
9$521,955$132,424.34$28,878$178.05+$493.1KOCX
10$735,935$177,443.13$32,350$179.15+$703.6KOCX

OCX vs VIG: Complete Analysis 2026

OCXStock

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

Full OCX Calculator →

VIGETF

Seeks to track the performance of the S&P U.S. Dividend Growers Index.Passively managed, full-replication approach.Fund remains fully invested.Large-cap equity, emphasizing stocks with a record of growing their dividends year over year.Low expenses minimize net tracking error.With respect to 75% of its total assets, the fund may not: (1) purchase more than 10% of the outstanding voting securities of any one issuer or (2) purchase securities of any issuer if, as a result, more than 5% of the fund’s total assets would be invested in that issuer’s securities; except as may be necessary to approximate the composition of its target index. This limitation does not apply to obligations of the U.S. government or its agencies or instrumentalities.

Full VIG Calculator →
📬

Get this OCX vs VIG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OCX vs SCHDOCX vs JEPIOCX vs OOCX vs KOOCX vs MAINOCX vs DGROOCX vs NOBLOCX vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.